Sol-Gel Technologies Ltd.: Clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel has two positive Phase 3 programs, both with PDUFA dates in 2021: Epsolay has the potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product for rosacea with PDUFA date on April 26th. Twyneo has the potential to be the first acne treatment that contains a fixed dose combination of BPO and tretinoin with PDUFA date on August 1st. Additional branded pipeline assets include SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctuate palmoplantar keratoderma, and PC assets tapinarof and roflumilast. Sol-Gel has revenue from several generic collaborations; it was also informed by its collaboration partner that the launch of an additional FDA-approved generic drug is expected in 2Q21. Annual sales of the brand name product exceeded $180 million in the US in 2019.